SCHEMBL30765677

SCHEMBL30765677

O=C(O)Cn1c(-c2ccccc2)ncc(-c2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
HSD17B10 Q99714 2/20 0.49
HPGD P15428 3/20 0.46
ALDH1A1 P00352 2/20 0.46
APEX1 P27695 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
ALOX15 P16050 1/20 0.42
ELANE P08246 1/20 0.42
AKR1B10 O60218 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GLA P06280 1/20 0.41
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765989 0.85 KDM4E (0.51) KDM4EHSD17B10HPGDALDH1A1L3MBTL1
SCHEMBL6239360 0.84 CMA1 (0.53) KDM4EHSD17B10ELANE
Hydrochloric Acid SCHEMBL6805327 0.82 CMA1 (0.53) KDM4EHSD17B10ELANE
SCHEMBL6804111 0.82 CMA1 (0.53) KDM4EHSD17B10ELANE
SCHEMBL6241617 0.79 KDM4E (0.44) KDM4EHSD17B10HPGDALDH1A1APEX1
SCHEMBL7965688 0.79 KDM4E (0.45) KDM4EHSD17B10HPGDALDH1A1L3MBTL1
SCHEMBL6259007 0.78 ELANE (0.47) KDM4EHSD17B10HPGDALDH1A1APEX1
SCHEMBL5728202 0.78 ELANE (0.54) KDM4EHSD17B10HPGDELANE
SCHEMBL30765762 0.77 ALDH1A1 (0.42) KDM4EHSD17B10HPGDALDH1A1ALOX15
SCHEMBL6240894 0.77 ELANE (0.51) KDM4EHSD17B10HPGDALDH1A1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed